These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 21819331)

  • 1. Surveillance and management of multidrug-resistant microorganisms.
    Orsi GB; Falcone M; Venditti M
    Expert Rev Anti Infect Ther; 2011 Aug; 9(8):653-79. PubMed ID: 21819331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment.
    McDonald LC
    Clin Infect Dis; 2006 Jan; 42 Suppl 2():S65-71. PubMed ID: 16355319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
    Kaye KS; Pogue JM
    Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility patterns of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin, and tigecycline.
    Somily AM; Absar MM; Arshad MZ; Al Aska AI; Shakoor ZA; Fatani AJ; Siddiqui YM; Murray TS
    Saudi Med J; 2012 Jul; 33(7):750-5. PubMed ID: 22821309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The challenge of multidrug resistance: the treatment of gram-negative rod infections.
    Levin AS; Oliveira MS
    Shock; 2008 Oct; 30 Suppl 1():30-3. PubMed ID: 18704012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tigecycline.
    Pankey GA
    J Antimicrob Chemother; 2005 Sep; 56(3):470-80. PubMed ID: 16040625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of multidrug-resistant Gram-negative infections in children.
    Hsu AJ; Tamma PD
    Clin Infect Dis; 2014 May; 58(10):1439-48. PubMed ID: 24501388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options.
    Maragakis LL; Perl TM
    Clin Infect Dis; 2008 Apr; 46(8):1254-63. PubMed ID: 18444865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.
    Kiratisin P; Chongthaleong A; Tan TY; Lagamayo E; Roberts S; Garcia J; Davies T
    Int J Antimicrob Agents; 2012 Apr; 39(4):311-6. PubMed ID: 22386743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
    Dong SX; Wang JT; Chang SC
    J Microbiol Immunol Infect; 2012 Dec; 45(6):459-64. PubMed ID: 23102796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
    Garrison MW; Mutters R; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emergence of clinical resistance to tigecycline.
    Sun Y; Cai Y; Liu X; Bai N; Liang B; Wang R
    Int J Antimicrob Agents; 2013 Feb; 41(2):110-6. PubMed ID: 23127485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
    Hoban DJ; Bouchillon SK; Johnson BM; Johnson JL; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antimicrobial resistance of Gram negative bacilli isolated from tertiary-care hospitals in Colombia].
    Briceño DF; Correa A; Valencia C; Torres JA; Pacheco R; Montealegre MC; Ospina D; Villegas MV;
    Biomedica; 2010; 30(3):371-81. PubMed ID: 21713339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and microbiological characterization of pneumonia in mechanically ventilated patients.
    Medell M; Hart M; Marrero O; Espinosa F; Montes de Oca Z; Valdés R
    Braz J Infect Dis; 2012; 16(5):442-7. PubMed ID: 22975167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.
    Werarak P; Kiratisin P; Thamlikitkul V
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S126-38. PubMed ID: 20364567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.